Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Has announcements × Clear all

Phase

Phase 2 5 Phase 3 2 Phase 1 2 Phase 2/3 1

Status

Active not recruiting 4 Completed 3 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

umbralisib 1 ublituximab 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02793583 2022-07-21

UNITY-NHL

TG Therapeutics, Inc.

Phase 2/3 Terminated

710 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡